Repositioning Candidate Details
| Candidate ID: | R0287 |
| Source ID: | DB00805 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Minaprine |
| Synonyms: | 4-(2-((4-Methyl-6-phenyl-3-pyridazinyl)amino)ethyl)morpholine; 4-Methyl-3-(2-morpholinoethylamino)-6-phenylpyridazin; Minaprine; N-(4-Methyl-6-phenyl-3-pyridazinyl)-4-morpholineethanamine |
| Molecular Formula: | C17H22N4O |
| SMILES: | CC1=CC(=NN=C1NCCN1CCOCC1)C1=CC=CC=C1 |
| Structure: |
|
| DrugBank Description: | Minaprine is a psychotropic drug which has proved to be effective in the treatment of various depressive states. Like most antidepressants minaprine antagonizes behavioral despair. Minaprine is an amino-phenylpyridazine antidepressant reported to be relatively free of cardiotoxicity, drowsiness, and weight gain. |
| CAS Number: | 25905-77-5 |
| Molecular Weight: | 298.3828 |
| DrugBank Indication: | For the treatment of depression |
| DrugBank Pharmacology: | Minaprine is an amino-phenylpyridazine antidepressant reported to be relatively free of cardiotoxicity, drowsiness, and weight gain. Similar to other antidepressant treatments, minaprine attenuates the beta-adrenergic receptor function. Studies have also shown that minaprine improves memory consolidation and that repeated drug administration leads to potentiation of this effect. Moreover, the effects of minaprine on memory consolidation are related to its dopaminergic action. |
| DrugBank MoA: | Minaprine binds to serotonin type 2 receptors and to dopamine D1 and D2 type receptors. It also binds to the serotonin reuptake pump. Therefore, minaprine blocks the reuptake of both dopamine and serotonin. It is also, to a slight degree, cholinomimetic. Thus it may exhibit both mood-brightening and nootropic properties. It also acts as a reversible inhibitor of MAO-A (RIMA).It has also been found to inhibit acetylcholinesterase. |
| Targets: | Amine oxidase [flavin-containing] A inhibitor; 5-hydroxytryptamine receptor 2B antagonist; 5-hydroxytryptamine receptor 2A antagonist; 5-hydroxytryptamine receptor 2C antagonist; Acetylcholinesterase inhibitor; Sodium-dependent serotonin transporter inhibitor; Dopamine D1 receptor agonist; Dopamine D2 receptor agonist; Muscarinic acetylcholine receptor M1 agonist |
| Inclusion Criteria: | Indication associated |
